These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29743023)

  • 1. Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds.
    Anadol R; Schnitzler K; Lorenz L; Weissner M; Ullrich H; Polimeni A; Münzel T; Gori T
    BMC Cardiovasc Disord; 2018 May; 18(1):92. PubMed ID: 29743023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence, Clinical Presentation, and Predictors of Clinical Restenosis in Coronary Bioresorbable Scaffolds.
    Polimeni A; Weissner M; Schochlow K; Ullrich H; Indolfi C; Dijkstra J; Anadol R; Münzel T; Gori T
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1819-1827. PubMed ID: 28935073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.
    Hommels TM; Hermanides RS; Rasoul S; Berta B; IJsselmuiden AJJ; Jessurun GAJ; Benit E; Pereira B; De Luca G; Kedhi E
    Cardiovasc Diabetol; 2019 Mar; 18(1):25. PubMed ID: 30851731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre GHOST-EU Registry.
    Capranzano P; Capodanno D; Brugaletta S; Latib A; Mehilli J; Nef H; Gori T; Lesiak M; Geraci S; Pyxaras S; Mattesini A; Münzel T; Araszkiewicz A; Caramanno G; Naber C; Di Mario C; Sabatè M; Colombo A; Wiebe J; Tamburino C
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):444-453. PubMed ID: 29068130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions - Implications from early clinical experience during daily practice.
    Wiebe J; Dörr O; Bauer T; Liebetrau C; Boeder N; Möllmann H; Hamm CW; Nef HM
    Cardiovasc Revasc Med; 2016; 17(5):313-7. PubMed ID: 27085220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics, Predictors, and Mechanisms of Thrombosis in Coronary Bioresorbable Scaffolds: Differences Between Early and Late Events.
    Gori T; Weissner M; Gönner S; Wendling F; Ullrich H; Ellis S; Anadol R; Polimeni A; Münzel T
    JACC Cardiovasc Interv; 2017 Dec; 10(23):2363-2371. PubMed ID: 29216999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of very long-term clinical and angiographic outcomes of bare metal stent implants between patients with and without type 2 diabetes.
    Lu CH; Tsai ML; Chen CC; Hsieh MJ; Chang SH; Wang CY; Lee CH; Chen DY; Yang CH; Hsieh IC
    Prim Care Diabetes; 2017 Oct; 11(5):445-452. PubMed ID: 28576662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials.
    Campos CM; Caixeta A; Franken M; Bartorelli AL; Whitbourn RJ; Wu CJ; Li Paul Kao H; Rosli MA; Carrie D; De Bruyne B; Stone GW; Serruys PW; Abizaid A;
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):387-395. PubMed ID: 28471086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of percutaneous coronary intervention with the Absorb bioresorbable scaffold: data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Grimfjärd P; James S; Persson J; Angerås O; Koul S; Omerovic E; Varenhorst C; Lagerqvist B; Erlinge D
    EuroIntervention; 2017 Dec; 13(11):1303-1310. PubMed ID: 28781242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioresorbable scaffold implantation in patients with indication for oral anticoagulation: A propensity matched analysis.
    Boeder NF; Johnson V; Dörr O; Wiebe J; Elsässer A; Möllmann H; Hamm CW; Nef HM; Bauer T
    Int J Cardiol; 2017 Mar; 231():73-77. PubMed ID: 27899203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry.
    Ortega-Paz L; Capodanno D; Giacchi G; Gori T; Nef H; Latib A; Caramanno G; Di Mario C; Naber C; Lesiak M; Capranzano P; Wiebe J; Mehilli J; Araszkiewicz A; Pyxaras S; Mattesini A; Geraci S; Naganuma T; Colombo A; Münzel T; Sabaté M; Tamburino C; Brugaletta S
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):812-818. PubMed ID: 27515568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Strut Width in Periprocedural Myocardial Infarction: A Propensity-Matched Comparison Between Bioresorbable Scaffolds and the First-Generation Sirolimus-Eluting Stent.
    Kawamoto H; Panoulas VF; Sato K; Miyazaki T; Naganuma T; Sticchi A; Figini F; Latib A; Chieffo A; Carlino M; Montorfano M; Colombo A
    JACC Cardiovasc Interv; 2015 Jun; 8(7):900-9. PubMed ID: 26003020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes following target lesion revascularization for bioresorbable scaffold failure.
    Tanaka A; Ruparelia N; Kawamoto H; Sticchi A; Figini F; Carlino M; Chieffo A; Montorfano M; Latib A; Colombo A
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):832-6. PubMed ID: 26331577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions: The BONITO Registry (Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions).
    Azzalini L; Giustino G; Ojeda S; Serra A; La Manna A; Ly HQ; Bellini B; Benincasa S; Chavarría J; Gheorghe LL; Longo G; Miccichè E; D'Agosta G; Picard F; Pan M; Tamburino C; Latib A; Carlino M; Chieffo A; Colombo A
    Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27765802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry.
    Wiebe J; Hoppmann P; Colleran R; Kufner S; Valeskini M; Cassese S; Schneider S; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1222-1229. PubMed ID: 28641842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformability in everolimus-eluting bioresorbable scaffolds compared with metal platform coronary stents in long lesions.
    Fam JM; Ishibashi Y; Felix C; Zhang BC; Diletti R; van Mieghem N; Regar E; van Domburg R; Onuma Y; van Geuns RJ
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1863-1871. PubMed ID: 28685314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison.
    Wiebe J; Dörr O; Ilstad H; Husser O; Liebetrau C; Boeder N; Bauer T; Möllmann H; Kastrati A; Hamm CW; Nef HM
    JACC Cardiovasc Interv; 2017 Mar; 10(5):477-485. PubMed ID: 28216214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.